Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors
19 avr. 2022 08h05 HE
|
Ceapro Inc.
EDMONTON, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
13 avr. 2022 09h00 HE
|
Ceapro Inc.
– FY 2021 record sales of $17,200,000 compared to $15,100,000 for FY 2020, representing a 14% increase year over year; Ceapro’s best sales performance in Company history – Net profit of $2,842,000...
Ceapro Signs Exclusive Long-Term Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise
10 mars 2022 09h05 HE
|
Ceapro Inc.
- Symrise to distribute and commercialize Ceapro’s high value active ingredients in the cosmetic market - - Supply and distribution agreement provides Symrise with exclusivity for several major key...
Ceapro Bolsters Board of Directors with Appointment of Top Executive from Global Pharmaceutical Industry
02 mars 2022 08h00 HE
|
Ceapro Inc.
EDMONTON, Alberta, March 02, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. to Present at the Virtual Investor 2022 Top Picks Conference
20 janv. 2022 09h05 HE
|
Ceapro Inc.
EDMONTON, Alberta, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Announces R&D Funding to Support PGX Technology Project
29 nov. 2021 08h05 HE
|
Ceapro Inc.
– PGX Technology further recognized as a disruptive technology – Additional support paves the way for the manufacturing of pharmaceutical-grade yeast beta glucan (YBG) EDMONTON, Alberta, Nov. 29,...
Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational Highlights
17 nov. 2021 09h00 HE
|
Ceapro Inc.
– Increased R&D activities focused on the completion of a clinical trial for oat beta glucan as a potential cholesterol reducer and on the development of yeast beta glucan as a potential inhalable...
Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol Levels
17 nov. 2021 07h00 HE
|
Ceapro Inc.
EDMONTON, Alberta, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Provides Update on Development of an Inhalable Therapeutic Using Yeast Beta Glucan Processed with Pressurized Gas eXpanded Technology (PGX-YBG)
11 nov. 2021 08h35 HE
|
Ceapro Inc.
McMaster’s research team discovers new mechanism of action for PGX-YBG PGX-YBG demonstrates ability to reprogram macrophages on its own PGX-YBG may be a suitable therapeutic solution for patients...
Ceapro Inc. to Present at the Virtual Investor Roundtable Event
10 nov. 2021 09h00 HE
|
Ceapro Inc.
EDMONTON, Alberta, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...